In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
about
Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditisUse of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptideActivities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendationsTeicoplanin in the treatment of gram-positive-bacterial endocarditis.Comparative antibacterial activity of Vancocin and generic vancomycin.In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibioticIn vitro susceptibilities of four species of coagulase-negative staphylococci.Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficileIdentification, clinical distribution, and susceptibility to methicillin and 18 additional antibiotics of clinical Staphylococcus isolates: nationwide investigation in Italy.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Glycopeptide antibiotics.Current problems of chemotherapy of infections with coagulase-negative staphylococci.TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureusEfficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteriaIn vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.In vitro activity and human pharmacokinetics of teicoplanin.In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species.Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine.Thermodynamic analysis of the interaction of the antibiotic teicoplanin and its aglycone with cell-wall peptides.Growth and enrichment medium for detection and isolation of Shiga toxin-producing Escherichia coli in cattle feces.Activity of teicoplanin against coagulase-negative staphylococci isolated from patients undergoing continuous peritoneal dialysis.
P2860
Q24645282-391DB323-4652-4C0B-B649-4A257888DF59Q33751791-2211FBD4-7870-4104-B1FF-EA73EA837541Q35138478-24DCAE6D-85F2-4981-B66E-67D0093654CCQ35329160-0D2F99DA-82CF-4756-BB2D-DDA08B46DEBDQ35344121-B6091F95-C046-42A9-8F43-90FB4D8C3D15Q35537147-4A1B0E5D-0026-44E0-9A07-EF7783DB8D46Q35570582-F63B8A6D-20F2-4A45-ABF6-95CBDFCB8096Q35575038-37CBD55E-31BA-4F5F-B01F-0164DCEAC761Q35648347-D2ED3395-F030-47B4-8532-E127CB44FCF8Q35758671-971FCE89-EB3E-4936-9CC0-A9CDAA95AC94Q35825738-9D83E7A3-3A19-4C6C-B51A-2D307238FD9DQ35893075-26AE052B-CE61-4DB3-AB33-B1059E3088F8Q36752727-9F4A471F-951E-4AB3-8002-57CAD6FD3026Q37265050-5D9C1E84-395B-4AF4-BEE3-EA070C1DB6ABQ37821604-B6C7F945-9D8B-4E33-8596-B37ECF9F9F97Q39637662-B8C43C4A-2787-4406-8DEA-4F7A58A429C5Q39741092-6CA1F558-E201-4408-9FC0-80AD5A05438EQ39779720-21FD18A1-112C-4393-948C-591F6A01747AQ39815914-58FB32F5-4DC4-4A00-9DE9-A75C62D7DE76Q39817718-D78836DA-F023-4493-B5A3-CF87E235BFEAQ39835039-0E6BE4FF-378F-45FC-87A1-F5136A634848Q39849439-72186FD7-389C-4623-BDCA-1178BB4016A2Q39849719-EB877D04-5D33-4E80-91F7-596164292763Q39850636-0AEF7784-AA4F-4E90-BC23-246A64ECC1B0Q42824920-32AD5680-03AF-4710-ABB1-0F4B5F807DF0Q46561142-20E59809-CDEB-4CE9-BA13-A17A9A42562EQ54433710-69C394D1-AEE9-4E6D-B83A-6E3EBEB2112D
P2860
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@en
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@nl
type
label
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@en
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@nl
prefLabel
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@en
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@nl
P2093
P2860
P356
P1476
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.
@en
P2093
P2860
P304
P356
10.1128/AAC.23.3.402
P407
P577
1983-03-01T00:00:00Z